Condition: Plaque Psoriasis · Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
This description comes directly from the study's public registry record.
Molly Lin · +86 15198230043 · molly.lin@innocarepharma.com
Always discuss trial participation with your own doctor first.
| Shanghai Dermatology Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07251998